- Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings, published in Nature Genetics, identify potential new targets for drug treatments.
Tags: ChildhoodCancer, Genomics, TargetedTherapy, BrainTumors
- Investigators at Dana-Farber led by Leena Gandhi, MD, PhD, report a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that frees up an immune system attack on tumor cells.
Tags: LungCancer, Immunotherapy
- Beginning this summer, Dana-Farber Cancer Institute will provide hematology and medical oncology care under a new agreement at St. Elizabeth's Medical Center, a part of the Steward Health Care System.
- Karen Fasciano, PsyD, clinical psychologist and director of the Young Adult Program at Dana-Farber/Brigham and Women's Cancer Center, offers some tips for young adult patients.
- A study by researchers at Dana-Farber Cancer Institute shows that not all doctors are ready to embrace tests that look for hundreds of DNA changes in patients' tumor samples, while others plan to offer this type of cancer gene testing to most of their patients.
Tags: Genomics, TargetedTherapy
- March is National Nutrition Month and Dana-Farber Cancer Institute has created a Web-based video series that explores how diet can help support health and wellbeing during and after cancer treatment.
Tags: Nutrition, PatientSupport, Survivorship, CopingWithCancer
- Genomic profiling of a patient's advanced bladder cancer explained his "exceptional response" to the drug everolimus. The scientists say this technique can help identify other patients who may respond to the drug.
- Terminal cancer patients who receive chemotherapy in the last months of their lives are less likely to die where they want and are more likely to undergo invasive medical procedures than those who do not receive chemotherapy.
Tags: chemotherapy, EndOfLife
- Nivolumab, a drug that unleashes the immune system to attack cancer, now shown to produce lasting remissions and hold the disease in check — for more than two years, in some cases — in many patients with advanced melanoma, according to a new study by Dana-Farber researchers and colleagues.
Tags: Melanoma, Immunotherapy
- A normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia, to promote progression of the cancer and its resistance to treatment with FLT3-blocking drugs, which may explain relatively poor results in clinical studies. In a mouse model, treatment with a combination of drugs to inhibit the two enzymes was more effective than treatment with either drug alone.
Tags: chemotherapy, BasicResearch, ChildhoodCancer, Leukemia
Showing 31-40 of 513 items